Introduction
============

Dendritic cells (DCs) are antigen-presenting cells with an important role in the innate and adaptive immune system. In skin lesions, cutaneous DCs (Langerhans cells, dermal DCs and plasmacytoid DCs) are involved in immune activation in inflammatory benign lesions (psoriasis, lupus erythematosus (LE), spongiotic dermatitis), as well as in malignant lymphoid proliferations (mycosis fungoides, cutaneous T-cell lymphoma). DCs are a modulator of skin immunity, with a significant role in immunological reactions as well as in immune tolerance to various factors, including tumor cells and auto-immune stimuli ([@b1-ol-0-0-10097]). In antitumor immune defense, DCs are antigen-presenting cells for CD8^+^ T-lymphocytes via histocompatibility complex class I ([@b2-ol-0-0-10097]).

Recent studies have defined DCs as immune regulators of the skin with a key role in various complex reactions such as antitumoral immunity, maintenance of immune homeostasis, modulation of T-cell function, wound healing and interaction with skin grafts and immune evasion of HIV ([@b3-ol-0-0-10097]--[@b6-ol-0-0-10097]).

Since DCs are located within the epidermis and dermis as well, their activation intervenes early during the interaction with environmental factors. Their migrating capacity to local lymph nodes is involved in regional and systemic response to skin injuries ([@b5-ol-0-0-10097]).

From our point of view, the study of DCs in inflammatory and tumoral skin lesions should concern two interconnected aspects: the distribution of DCs and their role in lesional mechanisms.

Their special pattern of distribution in inflammatory dermatitis and skin lymphomas is useful not only to better understand pathophysiologic mechanisms involved in these diseases, but also as an adjuvant tool for diagnosis. In addition, they may play an important role in therapeutical approaches in inflammatory skin diseases ([@b7-ol-0-0-10097],[@b8-ol-0-0-10097]).

Our team previously presented studies concerning DC distribution in cutaneous melanoma ([@b1-ol-0-0-10097]) as well as in mycosis fungoides vs. inflammatory dermatoses ([@b9-ol-0-0-10097],[@b10-ol-0-0-10097]). This preoccupation for DCs revealed interesting results that prompted the initiation of this study.

Thus, in melanoma, DCs are especially found in areas of regression, being involved in the immune mechanisms that determine tumor cell destruction. Moreover, DCs have significant patterns of distribution in areas of regression (nodular pattern) compared with areas without regression (predominantly diffuse pattern) ([@b2-ol-0-0-10097],[@b11-ol-0-0-10097]). These data suggest that DCs are active players in melanoma\'s regression and could be used as therapeutical targets to enhance this natural process of tumor clearance ([@b2-ol-0-0-10097],[@b12-ol-0-0-10097]).

On the other hand, in spongiotic dermatitis, we described a nodular pattern of DC distribution, while in the early stage mycosis fungoides (patch/plaque stage), DCs were distributed in clusters with arachnoid extensions. To the best of our knowledge, this feature is very useful in difficult differential diagnosis of mycosis fungoides vs. spongiotic dermatitis ([@b9-ol-0-0-10097]).

Different studies describe specific roles of skin DCs in various inflammatory and tumoral conditions.

In psoriasis, a chronic inflammatory skin model type 1 autoimmune disease with a strong interferon-γ (IFN-γ) T helper 1 (Th1) signal ([@b13-ol-0-0-10097]--[@b15-ol-0-0-10097]), DCs interact with CD4^+^ T cells and keratinocytes, controlling the fate of resident memory T cells and their response to various pro-inflammatory cytokines \[as interleukin (IL)-17, IL-1β, IL-23\] ([@b3-ol-0-0-10097],[@b13-ol-0-0-10097]).

In LE, a chronic autoimmune disease ([@b16-ol-0-0-10097],[@b17-ol-0-0-10097]), DCs (especially the plasmocytoid subtype) have an important role by producing type I IFN ([@b16-ol-0-0-10097]--[@b18-ol-0-0-10097]).

In spongiotic dermatitis, DCs initiate the inflammatory process after the ones located in epidermis are activated by environmental allergens ([@b19-ol-0-0-10097]--[@b21-ol-0-0-10097]). Also, they have a high affinity for IgE, determining the increase of antigen uptake ([@b5-ol-0-0-10097]).

In mycosis fungoides, a common cutaneous T-cell lymphoma with dermal infiltrate T cells, DCs have an unclear role in pathogenesis and progression ([@b22-ol-0-0-10097]). Their number is increased in all stages of the disease, with a greater emphasis on the tumor stage of the disease. They probably enhance tumor progression using the same pathway as regulatory T cells ([@b23-ol-0-0-10097]).

In cutaneous T-cell lymphoma, a neoplasm of memory inducer T cells ([@b24-ol-0-0-10097]--[@b26-ol-0-0-10097]), usually, neoplastic T cells, are mixed with a significantly increased number of Langerhans cells suggesting that the neoplastic process is triggered by DCs ([@b22-ol-0-0-10097]). In addition, immature DCs facilitate the survival of malignant T cells ([@b27-ol-0-0-10097]).

Patients and methods
====================

### Patients

We performed a retrospective study including 149 patients: 35 with mycosis fungoides, 35 with spongiotic dermatitis, 35 with psoriasis, 35 with lupus and 9 with cutaneous T-cell lymphomas (other than mycosis fungoides) diagnosed using histopathological and immunohistochemical staining between January 2012 and December 2016 at the Department of Pathology, Colentina University Hospital (Bucharest, Romania). Skin biopsies (incisional or excisional), received for histopathological diagnosis, were also included. All specimens were sampled according to the Pathology Guidelines of Medical Practice (Ministry of Health Regulation no. 1217/September 16, 2010 published in Official Monitor no. 723/October 29, 2010, annex 1), routinely processed for paraffin-embedding. The tissue was fixed in formaldehyde, solution 4%, buffered, pH 6.9, room temperature, 6--8 h. Then, 3 µm sections were cut and routinely stained with hematoxylin and eosin (H&E). All slides were examined by at least two senior pathologists and, in selected cases, immunohistochemical assays were performed for diagnosis. After establishing the diagnosis, 13 samples of mycosis fungoides, psoriasis, LE, spongiotic dermatitis and T cell lymphoma were included in the research cohort.

This study was approved by the Ethics Committee of Colentina University Hospital (Bucharest, Romania), and written informed consent was obtained from all the patients for the use of their tissue, after diagnosis for experimental purposes.

### Mehods

From each case we performed manual tissue multiarray (TMA) blocks. Tissue was extracted from the paraffin blocks and then embedded into recipient blocks, each including 8 samples from 8 patients. From each TMA block 3 µm sections were performed using a semi-automatic Leica RM2245 rotary microtome. One slide was used for routine stain (H&E) and 10 immunohistochemical slides for CD1a, CD11c and langerin ([Table I](#tI-ol-0-0-10097){ref-type="table"}). As a detection system, we used Polymer Novolink (Leica Biosystems Nussloch GmbH, Nussloch, Germany). Immunohistochemical staining was analyzed using a microscope Olympus CX41 (Olympus, Tokyo, Japan).

Density and distribution of DCs were evaluated by two independent pathologists with expertise in dermatopathology. They estimated both the number of DCs and their pattern of distribution.

All data were registered in a database and statistically analyzed using Microsoft Excel (Microsoft, Redmond, Washington, USA) and IBM SPSS Statistics (version 22.0; IBM Corp., Armonk, NY, USA).

Results
=======

### Histological analysis of DC distribution

Histological examination of all cases identified various patterns of the DC distribution in the examined conditions: Clusters of DCs with arachnoid extension in mycosis fungoides, nodular pattern ([Fig. 1](#f1-ol-0-0-10097){ref-type="fig"}) in inflammatory lesions and dispersed distribution with peripheric accumulation and arachnoid in T-skin lymphomas ([Fig. 2](#f2-ol-0-0-10097){ref-type="fig"}). In mycosis fungoides and T-cell lymphoma, the number of DCs was increased both in epidermis and malignant infiltrate ([Fig. 3](#f3-ol-0-0-10097){ref-type="fig"}) compared with inflammatory lesions, in which the number of DCs was decreased in dermal inflammatory infiltrate while it remained in moderate numbers in epidermis.

In inflammatory lesions, spongiotic dermatitis ([Fig. 4](#f4-ol-0-0-10097){ref-type="fig"}), psoriasis ([Fig. 5](#f5-ol-0-0-10097){ref-type="fig"}) and LE ([Fig. 6](#f6-ol-0-0-10097){ref-type="fig"}), the predominant pattern was the nodular, followed by a dispersed pattern. The density of the DCs was decreased in inflammatory infiltrate compared with neoplastic conditions. The number of DCs in inflammatory lesions was higher in epidermis.

In mycosis fungoides ([Fig. 7](#f7-ol-0-0-10097){ref-type="fig"}) and cutaneous T-cell lymphoma ([Fig. 8](#f8-ol-0-0-10097){ref-type="fig"}), the predominant pattern was the arachnoid one. In cutaneous T-cell lymphoma, peripheric accumulation of DCs was observed, while an increased number of DCs was displayed in epidermis.

### Frequency of DCs

In neoplastic conditions, CD1a, CD11c and langerin-positive DCs were present in a higher number both in epidermis and neoplastic infiltrate ([Table II](#tII-ol-0-0-10097){ref-type="table"}).

In inflammatory lesions, the frequency of CD1a, CD11c and langerin-positive DCs was different. CD1a-positive DCs were rare in epidermis of the spongiotic dermatitis, psoriasis and frequently in LE. In inflammatory infiltrate, CD1a-positive DCs were rare in spongiotic dermatitis and LE and numerous in psoriasis. CD11c-positive DCs was rare in epidermis of the spongiotic dermatitis and frequent in psoriasis and LE. In inflammatory infiltrate, CD11c-positive DCs were numerous in psoriasis, LE and psoriasis. Langerin-positive DCs were rare in epidermis of the psoriasis, and LE, but they were frequent in spongiotic dermatitis. In inflammatory infiltrate, langerin-positive DCs were rare in spongiotic dermatitis and LE, but they were numerous in psoriasis.

Discussion
==========

Although the role of DCs in various skin diseases has been described by many studies, there are still very few recent studies concerning DC distribution patterns in skin inflammatory conditions and cutaneous malignant T-cell disorders. In our clinic, this is the second study analyzing the distribution patterns classified as arachnoid, diffuse and nodular in inflammatory cutaneous diseases and malignant T-cell conditions and identifying significant differences between distribution of DCs in benign and malignant skin lesions ([@b1-ol-0-0-10097],[@b9-ol-0-0-10097]).

These data are important, in the first place, for diagnosis since sometimes, because of the marked inflammatory infiltrate, differential diagnosis between malignant lymph cell proliferation and inflammatory dermatosis can be difficult. The pattern of distribution of DCs can help to differentiate these disorders, as a supplementary tool to usual histopathological and immunohistochemical features.

In addition, identification of significant differences between DC distribution in these two types of diseases is an indicator of different levels of involvement of DCs in the pathophysio-logical mechanisms of the disease. In inflammatory dermatoses, DCs have mostly a nodular distribution pattern, while in malignant lymph cell infiltrates, the most frequent pattern is an arachnoid distribution, intermingled with tumoral cells. These data are consistent with the fact that in inflammatory dermatoses, DCs most important role is activation by various antigens with subsequent trigger and modulation of inflammation, while in malignant lymph cell infiltrates, DCs have a more complex role as they are involved not only in triggering the disease, but also in tumor progression and regression.

In conclusion, immunohistochemical characterization of DC distribution can be an adjuvant tool in differential diagnosis in inflammatory dermatosis and skin lymphomas. At the same time, it can be correlated with functional studies explaining the role of skin DCs (local and migrated) in all phases of the disease.

This study identifies significant differences between benign and malignant skin conditions concerning DC distribution and can be integrated in a larger framework of immune interactions between the host and immune as well as tumoral factors involved in skin lesions.
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###### 

Antibodies used for the study.

  Primary antibody   Clone             Host    Supplier           Dilution   Specificity
  ------------------ ----------------- ------- ------------------ ---------- ---------------------
  CD1a               MTB1 monoclonal   Mouse   Leica Biosystems   1:50       Human CD1a molecule
  CD11c              5D11 monoclonal   Mouse   Leica Biosystems     1:100    Human CD11c antigen
  Langerin           12D6 monoclonal   Mouse   Leica Biosystems   1:50       Human langerin

###### 

Frequency of dendritic cells.

  Markers    Mycosis fungoides                                                          Cutaneous T-cell lymphoma                                                       Spongiotic dermatitis                                                             Psoriasis                                                                         Lupus erythematosus
  ---------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------- --------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------
  CD1a       Numerous DCs CD1a^+^ in neoplastic infiltrate and in epidermis             Numerous DCs CD1a^+^ in neoplastic infiltrate and in epidermis                  Rare DCs CD1a^+^ in inflammatory infiltrate and in epidermis                      Numerous DCs CD1a^+^ in inflammatory infiltrate and rare in epidermis             Rare DCs CD1a^+^ in inflammatory infiltrate and in epidermis
  CD11c      Numerous DCs CD11c-positive neoplastic infiltrate and rare in epidermis    Numerous DCs CD11c-positive in neoplastic infiltrate and in epidermis           Numerous DCs CD1a-positive in inflammatory infiltrate and rare in epidermis       Numerous DCs CD1a-positive in inflammatory infiltrate and in epidermis            Numerous CD1a DC-positive in inflammatory infiltrate and in epidermis
  Langerin   Numerous DCs langerin-positive in neoplastic infiltrate and in epidermis   Rare DCs langerin-positive in neoplastic infiltrate and numerous in epidermis   Rare DCs langerin-positive in inflammatory infiltrate and numerous in epidermis   Numerous DCs langerin-positive in inflammatory infiltrate and rare in epidermis   Rare DCs langerin-positive in inflammatory infiltrate and in epidermis
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